Studies suggest that a more aggressive approach to neck tightening procedures yields better results. Patients can experience significant pain and edema from these procedures that may require prescription medications to treat. The procedures cost thousands of dollars, raising questions about whether they're worth the cost for patients.
Many different types of peels are available to successfully treat a wide variety of skin conditions. Instances of post-inflammatory hyperpigmentation (PIH) that develop after healing of peel or laser treatments may require additional management. Attendance at workshops and use of prepackaged kits can help derms gain confidence in providing peel treatments to patients.
Available resources of the Center include human pathology specimens and database info on living consented patients. Techniques such as tissue imaging, gene expression analysis, T-cell receptor, sequencing studies, and CyTOF analyses are available. Visiting Scholar grants funds allow researchers to learn how to work with human tissue and how to use new techniques.
Emerging treatments are expected to help fill the need for safer and more effective therapies for atopic dermatitis (AD). Both systemic and topical treatments are needed to provide full and complete treatment for patients with AD. Targeting the specific axis or axes that control AD may contribute to developing personalized approaches to treatment
TNF inhibitors adalimumab and infliximab have evidence-based efficacy for the treatment of hidradentitis suppurativa (HS). Anti-interleukin inhibitors ustekinumab and anakinra also being evaluated in small studies for treatment of HS. Antibiotics, hormones, retinoids, steroids and laser therapies directly targeting the lesions round out an effective treatment plan for HS patients.
Biosimilars have the potential to lower the high costs of biologic treatments for patients suffering from chronic skin diseases. Although biosimilars have received FDA approval derms still have many questions about what they are and when they may be used appropriately. Patent wars and a lack of rules and regulations at the state level add to the confusion about using biosimilars.